# reload+after+2024-01-23 08:43:34.108886
address1§22 Cortlandt Street
address2§16th Floor
city§New York
state§NY
zip§10007
country§United States
phone§212 332 3241
fax§212 320 0245
website§https://www.axsome.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
fullTimeEmployees§502
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Herriot  Tabuteau M.D.', 'age': 55, 'title': 'Founder, Chairman, CEO & President', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 1320968, 'exercisedValue': 0, 'unexercisedValue': 87923912}, {'maxAge': 1, 'name': 'Mr. Nick  Pizzie CPA, M.B.A.', 'age': 48, 'title': 'Chief Financial Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 732941, 'exercisedValue': 0, 'unexercisedValue': 17865770}, {'maxAge': 1, 'name': 'Mr. Mark L. Jacobson', 'age': 40, 'title': 'COO & Secretary', 'yearBorn': 1983, 'fiscalYear': 2022, 'totalPay': 784661, 'exercisedValue': 0, 'unexercisedValue': 28273134}, {'maxAge': 1, 'name': 'Mr. Hunter  Murdock Esq.', 'age': 43, 'title': 'General Counsel & Secretary', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 735388, 'exercisedValue': 0, 'unexercisedValue': 909595}, {'maxAge': 1, 'name': 'Dr. Amanda  Jones Pharm.D.', 'age': 40, 'title': 'Senior Vice President of Clinical Development', 'yearBorn': 1983, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lori  Englebert M.B.A.', 'age': 45, 'title': 'Executive Vice President of Commercial & Business Development', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Joseph  Debrah-Afful CPA, M.B.A.', 'title': 'Director of Finance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.914
priceToSalesTrailing12Months§17.431295
currency§USD
dateShortInterest§1702598400
forwardEps§-3.19
pegRatio§-0.1
exchange§NGM
quoteType§EQUITY
shortName§Axsome Therapeutics, Inc.
longName§Axsome Therapeutics, Inc.
firstTradeDateEpochUtc§1447943400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§dc312fd5-deeb-376b-9b93-11451c06c191
gmtOffSetMilliseconds§-18000000
targetHighPrice§180.0
targetLowPrice§80.0
targetMeanPrice§116.25
targetMedianPrice§109.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§12
quickRatio§4.317
grossMargins§0.91103995
ebitdaMargins§-0.80026
trailingPegRatio§None
